^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    NeXT Personal™

    Company:
    Personalis
    Type:
    Laboratory Developed Test
    Related tests:

    Details

    Evidence
    News
    NeXT Personal, an advanced, tumor-informed liquid biopsy assay, was developed to deliver industry-leading MRD sensitivity in the range of 1-3 parts per million (PPM) representing a 10X-100X increase over other available methods. NeXT Personal is sample sparing, requiring only a single tube of blood (4mL plasma/15ng cfDNA), and 1mm3 of FFPE tumor tissue.
    Cancer:
    Solid Tumor
    Method:
    Circulating Tumor DNA (ctDNA)